Skip to content

Sienna Biopharmaceuticals, Inc.

Delisted

CIK 1656328fmd_06MNGZZ9BJCX34C20T8Y3RQ19GManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Sep 30, 2019, 16 periods

Latest annual · FY2018

Millions
Total revenues
0
Operating income
(76)
Net income
(73)
Free cash flow
(62)

Latest quarter · Q3 FY2019

Millions
Operating income
(6)
Net income
(4)
Free cash flow
(18)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2015 to FY2018
n/m

Sienna Biopharmaceuticals, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2018FY2017ChangeSource
Revenue$010-K 2019-03-14 · proof
Operating income-$76.5 million-$48.6 million10-K 2019-03-14 · proof
Net income-$73.5 million-$50.5 million10-K 2019-03-14 · proof
Cash from operating activities-$61.7 million-$41 million10-K 2019-03-14 · proof
Free cash flow-$61.7 million-$41.3 million10-K 2019-03-14 · proof
Total assets$107.3 million$136.8 million-21.6%10-K 2019-03-14 · proof
Total liabilities$80.7 million$45.6 million+76.8%10-K 2019-03-14 · proof
Cash and cash equivalents$48.5 million$74.5 million-34.8%10-K 2019-03-14 · proof
What was Sienna Biopharmaceuticals, Inc.'s revenue in fiscal 2018?
Sienna Biopharmaceuticals, Inc. reported revenue of $0 for fiscal 2018 (the year ended Dec 31, 2018). Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What was Sienna Biopharmaceuticals, Inc.'s operating income in fiscal 2018?
Sienna Biopharmaceuticals, Inc. reported operating income of -$76.5 million for fiscal 2018 (the year ended Dec 31, 2018), against -$48.6 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What was Sienna Biopharmaceuticals, Inc.'s net income in fiscal 2018?
Sienna Biopharmaceuticals, Inc. reported net income of -$73.5 million for fiscal 2018 (the year ended Dec 31, 2018), against -$50.5 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What was Sienna Biopharmaceuticals, Inc.'s cash from operating activities in fiscal 2018?
Sienna Biopharmaceuticals, Inc. reported cash from operating activities of -$61.7 million for fiscal 2018 (the year ended Dec 31, 2018), against -$41 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What was Sienna Biopharmaceuticals, Inc.'s free cash flow in fiscal 2018?
Sienna Biopharmaceuticals, Inc. reported free cash flow of -$61.7 million for fiscal 2018 (the year ended Dec 31, 2018), against -$41.3 million the year before. Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What are Sienna Biopharmaceuticals, Inc.'s total assets?
As of Dec 31, 2018, Sienna Biopharmaceuticals, Inc. reported total assets of $107.3 million, against $136.8 million a year earlier (-21.6%). Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What are Sienna Biopharmaceuticals, Inc.'s total liabilities?
As of Dec 31, 2018, Sienna Biopharmaceuticals, Inc. reported total liabilities of $80.7 million, against $45.6 million a year earlier (+76.8%). Source: the 10-K filed with the SEC on Mar 14, 2019. SEC
What are Sienna Biopharmaceuticals, Inc.'s cash and cash equivalents?
As of Dec 31, 2018, Sienna Biopharmaceuticals, Inc. reported cash and cash equivalents of $48.5 million, against $74.5 million a year earlier (-34.8%). Source: the 10-K filed with the SEC on Mar 14, 2019. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1656328&period_type=annual&limit=5"

Information only, not investment advice.